Curis Stock Price, News & Analysis (NASDAQ:CRIS)

$0.76 0.02 (2.72 %)
(As of 01/16/2018 04:00 PM ET)
Previous Close$0.76
Today's Range$0.74 - $0.82
52-Week Range$0.67 - $3.22
Volume3.23 million shs
Average Volume1.76 million shs
Market Capitalization$123.81 million
P/E Ratio-1.94
Dividend YieldN/A
Beta1.63

About Curis (NASDAQ:CRIS)

Curis logoCuris, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

Receive CRIS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:CRIS
CUSIP23126910
Phone+1-617-5036500

Debt

Debt-to-Equity Ratio1.24%
Current Ratio5.15%
Quick Ratio5.15%

Price-To-Earnings

Trailing P/E Ratio-1.93846153846154
Forward P/E Ratio-1.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.53 million
Price / Sales16.46
Cash FlowN/A
Price / CashN/A
Book Value$0.21 per share
Price / Book3.60

Profitability

Trailing EPS($0.39)
Net Income$-60,410,000.00
Net Margins-629.29%
Return on Equity-250.58%
Return on Assets-81.57%

Miscellaneous

Employees58
Outstanding Shares163,980,000

Curis (NASDAQ:CRIS) Frequently Asked Questions

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) issued its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.02. The biotechnology company earned $2.44 million during the quarter, compared to analyst estimates of $2.19 million. Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. The firm's revenue was up 38.6% compared to the same quarter last year. During the same period last year, the business earned ($0.21) EPS. View Curis' Earnings History.

When will Curis make its next earnings announcement?

Curis is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Curis.

Where is Curis' stock going? Where will Curis' stock price be in 2018?

3 equities research analysts have issued 12-month price targets for Curis' shares. Their predictions range from $6.00 to $7.00. On average, they anticipate Curis' stock price to reach $6.50 in the next year. View Analyst Ratings for Curis.

What are Wall Street analysts saying about Curis stock?

Here are some recent quotes from research analysts about Curis stock:

  • 1. According to Zacks Investment Research, "Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. " (1/9/2018)
  • 2. Cowen Inc analysts commented, "In our view, recent underperformance of CRIS shares is not reflective of the continued." (5/5/2017)

Who are some of Curis' key competitors?

Who are Curis' key executives?

Curis' management team includes the folowing people:

  • James R. McNab Jr., Independent Chairman of the Board (Age 73)
  • Ali Fattaey Ph.D., President, Chief Executive Officer, Director (Age 52)
  • James E. Dentzer, Chief Financial Officer, Chief Administrative Officer (Age 50)
  • David Tuck M.D., Chief Medical Officer (Age 65)
  • Lori A. Kunkel M.D., Director (Age 59)
  • Martyn D. Greenacre, Independent Director (Age 75)
  • Robert E. Martell M.D., Ph.D., Independent Director (Age 54)
  • Kenneth J. Pienta M.D., Independent Director (Age 57)
  • Marc Rubin M.D., Independent Director (Age 62)

How do I buy Curis stock?

Shares of Curis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Curis' stock price today?

One share of Curis stock can currently be purchased for approximately $0.76.

How big of a company is Curis?

Curis has a market capitalization of $123.81 million and generates $7.53 million in revenue each year. The biotechnology company earns $-60,410,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Curis employs 58 workers across the globe.

How can I contact Curis?

Curis' mailing address is 4 Maguire Rd, LEXINGTON, MA 02421-3112, United States. The biotechnology company can be reached via phone at +1-617-5036500 or via email at [email protected]


MarketBeat Community Rating for Curis (CRIS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  387
MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Curis (NASDAQ:CRIS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.50$6.50$6.00$6.67
Price Target Upside: 314.01% upside314.01% upside214.14% upside249.04% upside

Curis (NASDAQ:CRIS) Consensus Price Target History

Price Target History for Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/23/2017GuggenheimInitiated CoverageBuy$7.00N/AView Rating Details
5/15/2017CowenReiterated RatingBuyN/AView Rating Details
3/11/2017FBR & CoSet Price TargetBuy$6.00LowView Rating Details
10/12/2016Royal Bank of CanadaSet Price TargetBuy$7.00N/AView Rating Details
9/7/2016Robert W. BairdReiterated RatingOutperform$7.00N/AView Rating Details
3/1/2016SunTrust BanksInitiated CoverageBuy$3.00N/AView Rating Details
2/29/2016Roth CapitalReiterated RatingBuy$5.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Curis (NASDAQ:CRIS) Earnings History and Estimates Chart

Earnings by Quarter for Curis (NASDAQ:CRIS)

Curis (NASDAQ CRIS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018($0.09)N/AView Earnings Details
11/7/2017Q3 2017($0.09)($0.11)$2.19 million$2.44 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.09)($0.10)$2.08 million$2.10 millionViewListenView Earnings Details
5/4/2017Q1 17($0.09)($0.11)$1.98 million$2.13 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.10)($0.08)$1.97 million$2.40 millionViewListenView Earnings Details
11/3/2016Q316($0.10)($0.21)$1.84 million$1.80 millionViewListenView Earnings Details
8/4/2016Q216($0.09)($0.09)$2.05 million$1.70 millionViewListenView Earnings Details
5/9/2016Q116($0.08)($0.07)$2.30 million$1.70 millionViewListenView Earnings Details
2/29/2016Q415($0.12)($0.10)$2.98 million$2.10 millionViewListenView Earnings Details
11/9/2015Q315($0.08)($0.04)$2.82 million$2.00 millionViewN/AView Earnings Details
8/6/2015Q215($0.06)($0.06)$3.50 million$2.10 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$2.27 million$1.17 millionViewN/AView Earnings Details
2/24/2015Q4 14($0.07)($0.07)$2.69 million$2.00 millionViewN/AView Earnings Details
11/10/2014Q314($0.05)($0.06)$4.13 million$1.80 millionViewN/AView Earnings Details
8/7/2014Q214($0.06)($0.02)$3.46 million$4.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.07)($0.06)$1.88 million$1.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.08)($0.05)$1.59 million$1.52 millionViewN/AView Earnings Details
11/5/2013Q313($0.01)($0.02)$6.44 million$7.20 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.05)($0.02)$4.43 million$5.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.05)($0.06)$3.86 million$0.90 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.08)($0.15)$2.07 million$1.69 millionViewN/AView Earnings Details
11/6/2012Q312($0.08)($0.04)$1.01 million$0.60 millionViewN/AView Earnings Details
8/2/2012($0.05)($0.04)ViewN/AView Earnings Details
5/8/2012$0.02$0.03ViewN/AView Earnings Details
2/8/2012Q4 2011$0.06$0.08ViewN/AView Earnings Details
10/27/2011($0.07)($0.05)ViewN/AView Earnings Details
7/28/2011($0.07)($0.06)ViewN/AView Earnings Details
4/28/2011Q1 2011($0.07)($0.09)ViewN/AView Earnings Details
2/10/2011Q4 2010($0.06)($0.07)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.03)($0.02)ViewN/AView Earnings Details
8/3/2010Q2 2010($0.04)($0.03)ViewN/AView Earnings Details
5/6/2010Q1 2010$0.05$0.06ViewN/AView Earnings Details
2/25/2010Q4 2009($0.05)($0.04)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.06)($0.06)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.07)($0.07)ViewN/AView Earnings Details
5/5/2009Q1 2009$0.01$0.02ViewN/AView Earnings Details
2/10/2009Q4 2008($0.03)($0.03)ViewN/AView Earnings Details
10/28/2008Q3 2008($0.07)ViewN/AView Earnings Details
7/30/2008Q2 2008($0.03)ViewN/AView Earnings Details
4/30/2008Q1 2008($0.05)ViewN/AView Earnings Details
2/14/2008Q4 2007$0.07ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Curis (NASDAQ:CRIS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.31)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.07)($0.07)($0.07)
Q2 20181($0.08)($0.08)($0.08)
Q3 20181($0.08)($0.08)($0.08)
Q4 20181($0.08)($0.08)($0.08)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Curis (NASDAQ:CRIS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Curis (NASDAQ CRIS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.07%
Institutional Ownership Percentage: 55.22%
Insider Trades by Quarter for Curis (NASDAQ:CRIS)
Institutional Ownership by Quarter for Curis (NASDAQ:CRIS)

Curis (NASDAQ CRIS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2017Marc RubinDirectorBuy25,000$0.98$24,500.0051,596View SEC Filing  
11/15/2017Ali Ph.D. FattaeyCEOBuy50,000$1.06$53,000.00115,890View SEC Filing  
5/5/2017James R McnabDirectorSell76,276$2.04$155,603.04879,688View SEC Filing  
5/2/2017James R McnabDirectorSell116,708$2.38$277,765.04View SEC Filing  
4/27/2017James R McnabDirectorSell146,694$2.61$382,871.34912,426View SEC Filing  
4/24/2017James R McnabDirectorSell110,322$2.59$285,733.981,357,147View SEC Filing  
9/7/2016Discovery Technologie AurigeneMajor ShareholderBuy10,208,333$2.40$24,499,999.2027,328,464View SEC Filing  
5/27/2016Martyn D GreenacreDirectorSell15,000$1.69$25,350.0040,183View SEC Filing  
5/26/2016Kenneth I KaitinDirectorSell15,000$1.76$26,400.0031,800View SEC Filing  
12/30/2015Daniel R. PasseriDirectorSell14,400$3.01$43,344.00198,898View SEC Filing  
12/29/2015Daniel R. PasseriDirectorSell11,200$2.91$32,592.00198,898View SEC Filing  
12/28/2015Daniel R. PasseriDirectorSell13,600$2.85$38,760.00198,898View SEC Filing  
12/23/2015Daniel R. PasseriDirectorSell48,900$2.78$135,942.00198,898View SEC Filing  
12/21/2015Daniel R. PasseriDirectorSell289,000$2.99$864,110.00198,898View SEC Filing  
8/27/2014Ali Ph.D. FattaeyCEOBuy62,890$1.60$100,624.00View SEC Filing  
12/11/2013Ali Ph.D. FattaeyCOOBuy3,000$2.52$7,560.003,000View SEC Filing  
11/12/2013Michael GrayCFOBuy10,000$2.86$28,600.00107,304View SEC Filing  
11/8/2013Kenneth PientaDirectorBuy20,000$2.95$59,000.0030,000View SEC Filing  
8/16/2013James McnabDirectorSell50,000$4.00$200,000.001,079,688View SEC Filing  
12/6/2012Daniel R PasseriCEOBuy25,000$3.03$75,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Curis (NASDAQ CRIS) News Headlines

Source:
DateHeadline
Zacks: Analysts Anticipate Curis, Inc. (CRIS) Will Announce Quarterly Sales of $2.03 MillionZacks: Analysts Anticipate Curis, Inc. (CRIS) Will Announce Quarterly Sales of $2.03 Million
www.americanbankingnews.com - January 10 at 5:00 PM
Curis, Inc. (CRIS) Receives Consensus Recommendation of "Hold" from AnalystsCuris, Inc. (CRIS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 9 at 5:38 AM
 Brokerages Anticipate Curis, Inc. (CRIS) to Announce -$0.09 Earnings Per Share Brokerages Anticipate Curis, Inc. (CRIS) to Announce -$0.09 Earnings Per Share
www.americanbankingnews.com - January 8 at 9:36 AM
Curis, Inc. (CRIS) Expected to Post Quarterly Sales of $2.03 MillionCuris, Inc. (CRIS) Expected to Post Quarterly Sales of $2.03 Million
www.americanbankingnews.com - December 25 at 10:32 PM
ETFs with exposure to Curis, Inc. : December 25, 2017ETFs with exposure to Curis, Inc. : December 25, 2017
finance.yahoo.com - December 25 at 6:42 PM
Curis, Inc. (CRIS) Expected to Post Earnings of -$0.09 Per ShareCuris, Inc. (CRIS) Expected to Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - December 23 at 1:23 AM
Want To Invest In Curis Inc (NASDAQ:CRIS)? Here’s How It Performed LatelyWant To Invest In Curis Inc (NASDAQ:CRIS)? Here’s How It Performed Lately
finance.yahoo.com - December 21 at 5:01 PM
Curis (CRIS) vs. Cellular Dynamics International (ICEL) Financial SurveyCuris (CRIS) vs. Cellular Dynamics International (ICEL) Financial Survey
www.americanbankingnews.com - December 16 at 5:16 AM
Curis, Inc. (CRIS) Receives Consensus Recommendation of "Hold" from BrokeragesCuris, Inc. (CRIS) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 15 at 3:32 AM
ETFs with exposure to Curis, Inc. : December 12, 2017ETFs with exposure to Curis, Inc. : December 12, 2017
finance.yahoo.com - December 12 at 5:24 PM
Curis, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.03 MillionCuris, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.03 Million
www.americanbankingnews.com - December 7 at 10:00 PM
-$0.09 EPS Expected for Curis, Inc. (CRIS) This Quarter-$0.09 EPS Expected for Curis, Inc. (CRIS) This Quarter
www.americanbankingnews.com - December 5 at 7:12 AM
Curis (CRIS) Announces Upcoming Presentation at ASH - StreetInsider.comCuris (CRIS) Announces Upcoming Presentation at ASH - StreetInsider.com
www.streetinsider.com - December 1 at 5:11 PM
Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & ExpositionCuris Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition
finance.yahoo.com - December 1 at 5:11 PM
ETFs with exposure to Curis, Inc. : November 30, 2017ETFs with exposure to Curis, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 4:58 PM
Analyzing Curis (CRIS) and Its CompetitorsAnalyzing Curis (CRIS) and Its Competitors
www.americanbankingnews.com - November 26 at 11:20 AM
Should You Be Concerned About Curis Inc’s (CRIS) Investors?Should You Be Concerned About Curis Inc’s (CRIS) Investors?
finance.yahoo.com - November 24 at 4:02 PM
ETFs with exposure to Curis, Inc. : November 20, 2017ETFs with exposure to Curis, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 6:32 PM
Curis, Inc. (CRIS) Given Consensus Rating of "Hold" by BrokeragesCuris, Inc. (CRIS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 20 at 3:58 AM
 Brokerages Expect Curis, Inc. (CRIS) to Post -$0.09 Earnings Per Share Brokerages Expect Curis, Inc. (CRIS) to Post -$0.09 Earnings Per Share
www.americanbankingnews.com - November 16 at 7:08 PM
Insider Buying: Curis, Inc. (CRIS) Director Purchases 25,000 Shares of StockInsider Buying: Curis, Inc. (CRIS) Director Purchases 25,000 Shares of Stock
www.americanbankingnews.com - November 16 at 5:12 PM
Ali Ph.D. Fattaey Purchases 50,000 Shares of Curis, Inc. (CRIS) StockAli Ph.D. Fattaey Purchases 50,000 Shares of Curis, Inc. (CRIS) Stock
www.americanbankingnews.com - November 15 at 1:30 PM
3 Things In Biotech You Should Learn Today: November 13, 20173 Things In Biotech You Should Learn Today: November 13, 2017
seekingalpha.com - November 14 at 2:19 AM
Curis, Inc. (CRIS) Downgraded by Zacks Investment Research to "Sell"Curis, Inc. (CRIS) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - November 11 at 7:38 PM
Curis, Inc. :CRIS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017Curis, Inc. :CRIS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 10 at 5:25 PM
SunTrust Banks Comments on Curis, Inc.s FY2017 Earnings (CRIS)SunTrust Banks Comments on Curis, Inc.'s FY2017 Earnings (CRIS)
www.americanbankingnews.com - November 10 at 7:47 AM
Curis, Inc. (CRIS) Forecasted to Post FY2021 Earnings of ($0.11) Per ShareCuris, Inc. (CRIS) Forecasted to Post FY2021 Earnings of ($0.11) Per Share
www.americanbankingnews.com - November 9 at 4:34 PM
ETFs with exposure to Curis, Inc. : November 8, 2017ETFs with exposure to Curis, Inc. : November 8, 2017
finance.yahoo.com - November 8 at 10:37 PM
Curis, Inc. (CRIS) Posts  Earnings Results, Misses Estimates By $0.02 EPSCuris, Inc. (CRIS) Posts Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - November 8 at 3:02 PM
Curis Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Curis Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 8 at 4:40 AM
Curis, Inc. to Host Earnings CallCuris, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 11:38 PM
Curis Reports Third Quarter 2017 Financial ResultsCuris Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 11:38 PM
Curis reports 3Q lossCuris reports 3Q loss
finance.yahoo.com - November 7 at 11:38 PM
What Does Curis Inc’s (CRIS) Share Price Indicate?What Does Curis Inc’s (CRIS) Share Price Indicate?
finance.yahoo.com - November 7 at 11:38 PM
Edited Transcript of CRIS earnings conference call or presentation 7-Nov-17 1:30pm GMTEdited Transcript of CRIS earnings conference call or presentation 7-Nov-17 1:30pm GMT
finance.yahoo.com - November 7 at 11:38 PM
Curis, Upcoming SITC Meeting, Aurigene Collaboration and Analysts ReviewCuris, Upcoming SITC Meeting, Aurigene Collaboration and Analysts Review
finance.yahoo.com - November 6 at 6:48 PM
Curis to Present at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT SummitCuris to Present at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit
feeds.benzinga.com - November 3 at 7:28 AM
What You Must Know About Curis Inc’s (CRIS) Financial StrengthWhat You Must Know About Curis Inc’s (CRIS) Financial Strength
finance.yahoo.com - November 1 at 6:25 PM
Curis to Release Third Quarter 2017 Financial Results and Hold Conference Call on November 7, 2017Curis to Release Third Quarter 2017 Financial Results and Hold Conference Call on November 7, 2017
feeds.benzinga.com - November 1 at 7:47 AM
Head-To-Head Review: Curis (CRIS) & Its PeersHead-To-Head Review: Curis (CRIS) & Its Peers
www.americanbankingnews.com - November 1 at 5:06 AM
Comparing Curis (CRIS) and Its RivalsComparing Curis (CRIS) and Its Rivals
www.americanbankingnews.com - October 31 at 10:00 AM
Curis, Inc. (CRIS) Receives Average Recommendation of "Hold" from BrokeragesCuris, Inc. (CRIS) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 26 at 3:32 AM
Curis, Inc. (CRIS) to Release Quarterly Earnings on WednesdayCuris, Inc. (CRIS) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 6:52 AM
Curis, Inc. (CRIS) Coverage Initiated by Analysts at GuggenheimCuris, Inc. (CRIS) Coverage Initiated by Analysts at Guggenheim
www.americanbankingnews.com - October 23 at 6:20 PM
Curis, Inc. (CRIS) Upgraded by Zacks Investment Research to HoldCuris, Inc. (CRIS) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - October 16 at 8:10 PM
Zacks: Analysts Anticipate Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.17 MillionZacks: Analysts Anticipate Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.17 Million
www.americanbankingnews.com - October 10 at 8:51 AM
 Analysts Expect Curis, Inc. (CRIS) to Post -$0.09 EPS Analysts Expect Curis, Inc. (CRIS) to Post -$0.09 EPS
www.americanbankingnews.com - October 8 at 10:28 AM
Arsanis Announces Appointments of Chip Clark and David McGirr to Board of Directors and Promotion of Michael Gray to Chief Operating Officer and Chief Financial OfficerArsanis Announces Appointments of Chip Clark and David McGirr to Board of Directors and Promotion of Michael Gray to Chief Operating Officer and Chief Financial Officer
www.businesswire.com - October 4 at 11:41 AM
Curis, Inc. (CRIS) Given Consensus Recommendation of "Hold" by AnalystsCuris, Inc. (CRIS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - October 1 at 2:50 AM
Curis to Present at the Cantor Fitzgerald Global Healthcare Conference - GlobeNewswire (press release)Curis to Present at the Cantor Fitzgerald Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 23 at 2:38 AM

SEC Filings

Curis (NASDAQ:CRIS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Curis (NASDAQ:CRIS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Curis (NASDAQ CRIS) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.